Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine

Pfizer Begins a Phase 1/2 Study to Evaluate RSV Vaccine

Source: 
CP Wire
snippet: 

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. The highest risk of severe outcome from RSV occurs in the first months of life.